Blockade of AT1 Receptor Reduces Apoptosis, Inflammation and Oxidative Stress in Normotensive Rats with Intracerebral Hemorrhage.

Keun-Hwa Jung; Kon Chu; Soon-Tae Lee; Se-Jeong Kim; Eun-Cheol Song; Eun-Hee Kim; Dong-Kyu Park; Dong-In Sinn; Jeong-Min Kim; Manho Kim; Jae-Kyu Roh.

Stroke & Neural Stem Cell Laboratory, Clinical Research Institute, Department of Neurology, Seoul National University Hospital, Seoul, Republic of Korea (KHJ, KC, STL, SJK, ECS, EHK, DKP, DIS, JMK, MK, JKR), Program in Neuroscience, Neuroscience Research Institute of SNUMRC, Seoul National University, Seoul, Republic of Korea (KHJ, KC, STL, DIS, MK, JKR), Division of Epidemic Intelligence Service, Korea Center for Disease Control & Prevention, Seoul, Republic of Korea (KHJ).
Running title
Therapeutic effect of telmisartan on ICH

Correspondence and requests for materials should be addressed to:
Jae-Kyu Roh, MD, PhD.
Department of Neurology, Seoul National University Hospital
28, Yongon-Dong, Chongro-Gu, Seoul, 110-744, Republic of Korea.
Phone: +82-2-2072-3265 / Fax: +82-2-3672-4949 / e-mail: rohjk@snu.ac.kr

Number of text pages: 36
Number of tables: 0
Number of figures: 5
Number of references: 40
Number of words in Abstract: 202
Number of words in Introduction: 404
Number of words in Discussion: 1168

Abbreviations
ARB, Angiotensin II receptor blocker; ACE, angiotensin-converting enzyme; ATR, Angiotensin II receptor; ICH, intracerebral hemorrhage; COX2, cyclooxygenase-2; BBB, blood brain barrier; PPAR-γ, peroxisome proliferator-activated receptor-γ

Manuscript section: Neuropharmacology
Abstract

Angiotensin II exerts its CNS effects primarily via its receptors, AT1 and AT2, and participates in the pathogenesis of ischemia via AT1. The selective AT1 receptor blocker (ARB) is employed in the hypertension treatment, and exerts a variety of pleiotropic effects, including anti-oxidative, anti-apoptotic, and anti-inflammatory effects. In this study, we investigated the therapeutic effect of the ARB, telmisartan, in experimental intracerebral hemorrhage (ICH) in normotensive rats. ICH was induced via the collagenase infusion or autologous blood injection. Either telmisartan (30 mg/kg/d) or PBS was orally administered 2 hours after ICH induction. We evaluated hemorrhage volume, brain water content, and functional recovery, and performed the histological analysis for TUNEL, leukocyte infiltration, and microglia activation. A variety of intracellular signals, in terms of oxidative stress, apoptotic molecules and inflammatory mediators were also measured. Telmisartan reduced the hemorrhage volume, brain edema, and the inflammatory or apoptotic cells in the perihematomal area. Telmisartan was noted to induce the expression of eNOS and PPARγ, and to decrease the oxidative stress, apoptotic signals, TNF-α, and cyclooxygenase-2 expression. The telmisartan-treated rats exhibited less pronounced neurological deficits and recovered better. Thus, telmisartan appears to offer neural protection including anti-apoptosis, anti-inflammatory, and anti-oxidant benefits in the intracerebral hemorrhage rat model.
Introduction

Angiotensin II is a potent vasoconstrictor hormone, which is cleaved from angiotensinogen by renin and angiotensin-converting enzyme (ACE). In addition to its known vital role in both cardiovascular and fluid homeostasis, several lines of evidence implicate angiotensin II in the ischemic neuronal injury via the angiotensin II receptor subtype AT1 (AT1R) (Walter et al., 2002). Emerging evidences suggest that peripherally administered AT1R blockers (ARBs) can interact with AT1R in the brain across the blood-brain barrier (BBB) and reduce the infarct volumes in the experimental cerebral ischemia model (Dai et al., 1999; Nishimura et al., 2000; Yamakawa et al., 2003). Recently, ARBs were also proven to attenuate the inflammatory and oxidative stress (Ando et al., 2004; Zhou et al., 2005) and regulate the NOS isoenzymes in the brain (Ito et al, 2002). As a potent and highly selective AT1 receptor antagonist, telmisartan is described chemically as 4[(1,4-dimethyl-2-propyl(2,6-bi-1H-benzimidazol]-1-yl)methyl] [1,1-biphenyl]-2-carboxylic acid. This unique feature of telmisartan accounts for both its high receptor affinity and its excellent pharmacokinetic properties. Furthermore, telmisartan could confer effects other than the blockage of the AT1R, such as peroxisome proliferator-activated receptor-γ (PPAR-γ) activation (Benson et al., 2004).
The neurotoxicity associated with intracerebral hemorrhage (ICH) includes inflammation, oxidative stress, excitotoxicity, as well as toxic effects of blood degradation products (Wang et al., 2002; Chu et al., 2004; Jung et al., 2004; Lee et al., 2006). Recent works have indicated that the suppression of these responses can reduce the brain edema and improve functional outcomes in experimental ICH (Mayne et al., 2001; Peeling et al., 2001; Chu et al., 2004; Jung et al., 2004; Lee et al., 2006). Given that angiotensin II is the principal inducer of oxidative stress and inflammation (Rajagopalan et al., 1996; Iadecola et al., 2004; Chalupsky and Cai., 2005), the acute blockade of AT1R might exert beneficial effects in the hemorrhagic brain. However, to date, there was no study validating the effects of ARB as a potential therapeutic agent against ICH.

Peripherally administered telmisartan penetrates the BBB to inhibit the central effects of angiotensin II, via selective blockage of AT1R, but not AT2R (Gohlke et al., 2001). Since high doses of the antagonist, i.e. 10 mg/kg i.v. and 30 mg/kg p.o., could result in the nearly complete and sustained blockade of AT1R within the brain (Gohlke et al., 2001), we attempted to study the therapeutic effects of a high dose of telmisartan in normotensive rats in which ICH had been induced.
METHODS

Induction of intracerebral hemorrhage and telmisartan treatment

All the procedures were performed following an institutional approval in accordance with NIH Guide for the Care and Use of Laboratory Animals. Male Sprague-Dawley rats (12 weeks old; Orient, Seoul, Republic of Korea), weighing 200-220 gm, were randomly assigned to two experimental groups: ICH-vehicle group (ICH-only), and telmisartan-treated ICH group (ICH-TMS). Experimental ICH was induced via stereotaxic intrastriatal administration of bacterial collagenase type VII (Sigma), as has been described in other reports (Chu et al., 2004; Jung et al., 2004; Lee et al., 2006). Two hours after ICH induction, single oral dose of telmisartan (30 mg/kg/dose, p.o.; GSK, Korea; dissolved in 1 mL of PBS) was administered to the rats by feeding tubes. An equal amount of PBS was administered to the ICH-only group. We measured mean arterial blood pressure and arterial blood gases via a right femoral artery line (P.E.50 tubing). A small amount of heparinized saline was used to prevent clotting in the femoral artery and catheter. Physiological parameters were assessed 30 minutes before and after ICH induction, and 6 and 24 hours after telmisartan (or PBS) administration.

Autologous blood-injected ICH model
Additional experiments were also performed using a direct infusion of autologous blood into the rat striatum as an alternative model (Chu et al., 2004; Lee ST et al., 2006). A small craniotomy was performed using the same stereotactic coordinates and 300 µL of autologous unheparinized blood (from the femoral artery) was infused into the left striatum. In this model, we analyzed the brain water content in the ICH-only group and ICH-TMS group (30 mg/kg) that were initially treated 2 h after ICH induction and verified whether the effects of telmisartan would be comparable with those in the collagenase-induced ICH models.

**Behavioral Testing**

To examine the effects of the telmisartan on the neurological deficits of rats after ICH, a behavioral test was performed, by two investigators blinded to the treatment status of the rats, with modified limb placing tests (MLPT) (Chu et al., 2004; Jung et al., 2004; Lee et al., 2006). The test consists of 2 limb-placing tasks that assess the sensorimotor integration of the forelimb and the hind limb by checking responses to tactile and proprioceptive stimulation. First, the rat is suspended 10 cm over a table, and the stretch of the forelimbs toward the table is observed and evaluated: normal stretch, 0 points; abnormal flexion, 1 point. Next, the rat is positioned along the edge of the table, with its
forelimbs suspended over the edge and allowed to move freely. Each forelimb (forelimb, second task; hind limb, third task) is gently pulled down, and retrieval and placement are checked. Finally, the rat is placed toward the table edge to check for lateral placement of the forelimb. The 3 tasks are scored in the following manner: normal performance, 0 points; performance with a delay (2 seconds) and/or incomplete, 1 point; no performance, 2 points. A total of 7 points means maximal neurological deficit, and 0 points means normal performance. The animals were monitored during the period of postoperative recovery starting at 2 hours, 1, 7, 14, 21, and 28 days after ICH (n=6 per group).

**Hemorrhage volume and water content**

Hemorrhage volume was quantified at 24 hours or 72 hours, via a spectrophotometric assay conducted as described previously (Lee et al., 2006). Measurements from perfused brains subjected to ICH were compared with the standard curve, in order to obtain data in terms of hemorrhage volume (µL, n=6 per group). Seventy-two hours after the induction of ICH, the rats were anesthetized, sacrificed via decapitation and processed for measuring water content (n=6 per group) (Chu et al., 2004; Jung et al., 2004; Lee et al., 2006). Water content was expressed as a percentage of wet weight.
**Tissue preparation and immunohistochemistry.**

On day 3, the rats (n=6 per group) were re-anesthetized and perfused through the heart with 50 ml cold saline and 50 ml of 4% paraformaldehyde, in 0.1 mol/L PBS. We conducted immunostaining with antibodies against myeloperoxidase (MPO; 1:200, DAKO), and Ox-42 (1:500, chemicon), as previously described (Chu et al., 2004; Jung et al., 2004; Lee et al., 2006). We also conducted a TUNEL procedure for the *in situ* detection of DNA fragmentation, as was described previously (Chu et al., 2004; Jung et al., 2004; Lee et al., 2006). Coronal sections taken through the center of the needle insertion were analyzed via the counting of marker-specific cells throughout the entire section (3 sections per each antibody staining, 1 mm width). The total counts in these sections were converted to cell densities, in order to facilitate quantitation and comparison between the groups.

**Western blotting**

Twenty-four hours after the induction of ICH, the rats were sacrificed via decapitation, and the brains were immediately extracted (n=3 per group). Homogenates of the ipsilateral hemisphere were serially processed for western blotting, as described
previously (Jung et al., 2004; Lee et al., 2006). We used anti-eNOS (1:200; Pharmingen), anti-COX-2 (1:200; Pharmingen), anti-PPARγ (1:1000; Santa Cruz) and anti-β-actin antibody (Santa Cruz). Relative optical densities were obtained via comparison of the measured values with the mean value of the ICH-only group. For PPARγ, cytosolic and nuclear extracts were obtained. Tissues were homogenized with 300 µL of buffer (10 mmol/L N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid, pH 7.9; 1 mmol/L ethylenediamine tetraacetic acid (EDTA), 1 mmol/L EGTA, 10 mmol/L KCl, 1 mmol/L dithiothreitol (DTT), 0.5 mmol/L phenylmethylsulfonyl fluoride, 0.1 µg/mL aprotinin, 1 µg/mL leupeptin, 1 µg/mL Nα-p-tosyl-Llysine-chloromethyl ketone, 5 mmol/L NaF, 1 mmol/L NaVO4, 0.5 mol/L sucrose, and 10 mmol/L Na2MoO4). After 15 min, Nonidet P-40 (Roche) was added to reach a 0.5% concentration. The tubes were gently vortexed for 15 sec, and nuclei were collected by centrifugation at 8000g for 5 min. Supernatants were taken as a cytosolic fraction. The pellets were resuspended in 100 µL of buffer supplemented with 20% glycerol and 0.4 mol/L KCl and gently shaken for 30 min at 4°C. Nuclear protein extracts were obtained by centrifugation at 13,000g for 5 min, and aliquots of the supernatant were stored at -80°C. All steps of the fractionation were carried out at 4°C.
RT-PCR

We also conducted RT-PCR for Fas, FasL, TNF-α, and the AT1 / AT2 receptors (n=3 per group). The following primer sets were employed (25 cycles of 95°C, 58°C, and 72°C for 40s each): Fas: 5'-CAA GGG ACT GAT AGC ATC TTT GAG G-3' (sense) and 5'-TCC AGA TTC AGG GTC ACA GGT TG-3' (antisense); Fas-L: 5'-CAG CCC CTG AAT TAC CCA TGT C-3' (sense) and 5'-CAC TCC AGA GAT CAA AGC AGT TC-3' (antisense); TNF-α: 5'-TAC TGA ACT TCG GGG TGA TTG GTC C- 3' (sense) and 5'-CAG CCT TGT CCC TTG AAG AGA ACC-3' (antisense); AT1: 5'-AGA GCC GCA ACA TGA ACT CT-3' (sense) and 5'-CTG CAT AAG GCG GTT GGT AT-3' (antisense); AT2: 5'-AAT CTG GCT GTG GCT GAC TT-3' (sense) and 5'-AAG GAA GTG CCA GGT CAA TG-3' (antisense). The mRNA expression levels were normalized to GAPDH, and relative optical densities were determined via comparison of the measured values with the mean value of the ICH-only group.

Measurement of Caspase Activities

Caspase activities were characterized with ELISA kits (Caspase-3: Promega, Caspase-8: BD Biosciences, Caspase-9: Chemicon, n=3 per group), at 24 hours after the induction of ICH, as was previously described in other reports (Lee and Lo, 2003). Fluorescent
intensity was measured in a plate reader (FL600, Bio-Tek, excitation wavelength: 380 nm, emission wavelength: 460 nm).

**Evaluation of the oxidative stress**

One day after reperfusion, the rat brains were processed for the analysis of oxidative stress (n=6 per group). The oxidative fluorescent dye dihydroethidium (DHE, Sigma-Aldrich) was used to evaluate in situ production of superoxide (Jung et al., 2006).

Frozen, enzymatically intact brains were cut into 30-µm-thick sections and placed on a glass slide. The sections were simultaneously incubated with DHE (10 µM) in PBS for 30 minutes at 37°C, in a humidified chamber which was shielded from light. Coronal sections cut through the striatum (3 sections per brain, 1mm in width) were imaged in parallel. Superoxide-positive cells were manually counted in the eight regions around the striatum under x100 magnification using a laser scanning confocal microscopy with a Bio-Rad MRC 1024 (argon and krypton). Malondialdehyde (MDA) was estimated as an indicator of lipid peroxidation (n=3 per group). The brain tissues were homogenized with sodium phosphate buffer (pH 7.4). The reagents (1.5 ml acetic acid, 1.5 ml thiobarbituric acid, and 0.2 ml sodium dodecyl sulfate) were added to 0.1 ml of processed tissue sample. The mixture was then heated at 100°C for 60 minutes. The
mixture was cooled with tap water and 5 ml of n-butanol: pyridine (15:1) and 1 ml of distilled water was added. After centrifugation at 4000 rpm for 10 minutes, the organic layer was withdrawn and absorbance was measured at 532 nm using a spectrophotometer.

**Statistical Analysis**

All data in this study are presented as means ± standard deviations (SD). Data were analyzed by one-way analysis of variance (ANOVA) followed by Tukey’s test (when appropriate) or student’s t test if they were normally distributed (Kolmogorov-Smirnov test, \( p > 0.05 \)). In the case of blood pressure and behavior data, values of different time points were compared by two-way repeated measures ANOVA. Without normal distribution, we used the Mann-Whitney U test.

**RESULTS**

_Telmisartan prompted a functional recovery._

There were no significant differences in rectal temperature, arterial blood gases, and pH values among the experimental groups measured before and after ICH induction, and 6 and 24 hours after telmisartan (or PBS) administration. Post-ICH mean arterial pressure
(89.4 ± 5.8 mm Hg) did not significantly differ (P=0.302) from baseline pressure (87.5 ± 3.0 mm Hg). Mean arterial blood pressure at 6 hours after drug treatment was slightly lower than that after PBS administration, but this did not reach statistical significance (p=0.218, two-way repeated measures ANOVA). Data are available in the online supplementary table 1. The ICH-TMS group exhibited less profound deficits than did the ICH-only group at 1 day after the induction of ICH, and then continued to recover, with the difference between the two groups being statistically significant until at least 4 weeks after the induction of ICH (p<0.05, t-test). At week 4, the ICH-TMS group scored less than two points on the MLPT (Fig. 1a).

**Telmisartan reduced hemorrhage volume and brain water content.**

Telmisartan treatment attenuated the hemorrhage volume by 63%, as compared with the ICH-only group, 1 day after the induction of ICH, and by 86% at 3 days after ICH. The hemorrhage volumes were as follows: 43.4 ± 4.5 µL (day 1), 22.5 ± 4.5 µL (day 3) in the ICH-only group; 16.2 ± 2.5 µL (day 1), 3.1 ± 0.7 µL (day 3) in the ICH-TMS group (Fig. 1b; p<0.01, t-test). Brain water content in the lesioned (left) hemisphere was 81.81 ± 0.59 % in the ICH-only group, and 79.96 ± 0.41 % in the ICH-TMS group, with a significant difference (Fig. 1c; p<0.01, t-test). Brain water content in the non-lesioned
(right) hemisphere was 79.51 ± 0.56 % in the ICH-only group, and 79.47 ± 0.25 % in the ICH-TMS group (p=0.88, t-test). We also investigated the effect of telmisartan on brain water content in the autologous blood-injected ICH model, in which similar patterns of brain water content decrement were observed. In this model, the brain water contents of the hemorrhagic hemispheres were 80.8 ± 0.84 % in the ICH-only group and 79.42 ± 0.86 % in ICH-TMS (Fig. 1d; p<0.01, t-test).

Telmisartan reduced inflammatory cell infiltration and apoptotic cells.

TUNEL staining revealed a high density of positively-stained cells within the hemorrhage lesions themselves, as well as in the periphery of the lesions (Fig. 2a). Quantitative analysis revealed differences between the groups with regard to the number of TUNEL⁺ cells. The ICH-TMS group exhibited a significantly lower number of TUNEL⁺ cells (29.28 ± 5.98 cells/mm²) than did the ICH-only group (336.48 ± 26.27 cells/mm²; p<0.01, t-test; Fig. 2b). The ICH-TMS group was determined to possess significantly lower numbers of OX42⁺ microglial cells (ICH-TMS: 24.19 ± 6.10 cells/mm²; ICH-only: 90.28 ± 10.71 cells/mm²; p<0.01, t-test) and MPO⁺ neutrophils (ICH-TMS: 71.57 ± 20.87 cells/mm²; ICH-only: 195.84 ± 15.29 cells/mm²; p<0.01, t-test) than were observed in the ICH-only group, at 3 days after ICH (Fig. 2b).
Telmisartan downregulated the inflammatory and apoptotic molecules, combined with the upregulation of eNOS expression and PPARγ.

Western blotting revealed the upregulation of PPARγ and eNOS expression and the downregulation of COX2 induced by telmisartan treatment (Fig. 3a). Analysis of the 52-kd band corresponding to PPARγ demonstrated a 1.6 (± 0.1) fold increase in nuclear extracts of hemorrhagic brain tissue at 24 hours after the onset of ICH (Fig. 3c). The relative optical density of eNOS expression in the ICH-TMS group was 16.5 (± 1.2) times as high as in the ICH-only group (p<0.01, Mann-Whitney U test; Fig. 3d).

Meanwhile, COX2 expression was significantly attenuated in the ICH-TMS group (35% decrease vs ICH-only group; p<0.01, Mann-Whitney U test; Fig. 3e). Caspase activities were significantly reduced in the ICH-TMS group. Twenty-four hours after the induction of ICH, caspase-3 activity in the ICH-TMS group was determined to be significantly lower than that of the ICH-only group (62% decrease; p<0.01, Mann-Whitney U test; Fig. 3f). Caspase-8 and 9 activities were also shown to have been significantly reduced in the ICH-TMS group (31% decrease in caspase-8; 20 % decrease in caspase-9; p<0.01, t-test; Fig. 3f). In the analysis for the Angiotensin II receptors, AT1 and AT2, both of the ICH groups manifested marked increases in the expression of...
AT1 receptor mRNA after injury (3.5 fold increase: ICH-only; 3.1 folds increase: ICH-TMS), but exhibited no changes in the expression of the AT2 receptor (Fig. 4a and b). We measured the mRNA expression of cytokine-related genes, including TNF-α, Fas, and FasL. The hemorrhagic brain samples expressed abundant amounts of mRNA of these molecules, whereas the normal brains expressed them only at very low levels. Relative optical density analysis revealed the ICH-TMS group to have undergone a 94% decrease in the levels of TNF-α, a 56% decrease in Fas, and a 79% reduction in FasL mRNA levels, as compared with the ICH-only group (p<0.01, Mann-Whitney U test; Fig. 4c).

_Telmisartan reduced the oxidative stress in the hemorrhagic brain._

In the normal rats, few evidence of DHE-induced EtBr fluorescence was observed in the cortex and striatum. Superoxide-generating cells were increased in the hemorrhagic hemisphere, whereas only a few labeled cells were detected in the nonhemorrhagic hemisphere (Fig. 5a-c). Data from image analysis indicated that DHE-induced ethidium bromide fluorescence was 74% less pronounced in the ICH-TMS group than in the ICH-only group (Fig. 5d; p<0.05, t-test). These histological results were further supported by biochemical assay for MDA, lipid peroxidation product. Telmisartan
significantly decreased the levels of MDA (0.16 ± 0.04 µg/mg protein) as compared to the ICH-only group (0.31 ± 0.05 µg/mg protein) and normal group (0.07 ± 0.03 µg/mg protein) (Fig. 5e; p<0.05, Mann-Whitney U test).

DISCUSSION

In this study, telmisartan was shown to attenuate hemorrhage expansion and perihematomal edema formation, to induce neuroprotection, and to enhance functional recovery. These effects of telmisartan were associated with the inhibition or amelioration of apoptosis, oxidative stress, and neuroinflammation, rather than blood pressure reduction.

The dose (30 mg/kg, p.o.) used in this study was selected on the basis of pharmacokinetic study in the brain (Gohkle et al, 2001). Telmisartan concentrations measured in the cerebrospinal fluid following 8 days of consecutive daily oral treatment (1-30 mg/kg) ranged from 0.87 ± 0.27 ng/ml (1 mg/kg/d) to 46.5 ± 11.6 ng/ml (30 mg/kg/d). Following peripheral administration, telmisartan can penetrate the BBB in a dose- and time-dependent manner to inhibit centrally mediated effects of angiotensin II. Compared with losartan and irbesartan, the apparent higher capability of telmisartan to penetrate into the brain tissue might be explained by the hydrophobic/hydrophilic
properties of the drugs. Thus, we selected the telmisartan (30 mg/kg/d) as a potential drug against experimental ICH.

The AT1R mRNA level was shown to be increased in the hemorrhagic brain 24 hours after, whereas mRNA level of the AT2R was not affected. It is, therefore, conceivable to assume that the inhibition of central AT1R can considerably contribute to the observed beneficial effects of the telmisartan on neurological outcome of ICH. In a study involving heart transplantation donors, the systemic upregulation of AT1R was documented with the subsequent development of transplant vasculopathy and ICH (Yamani et al., 2004). The increased AT1R expression in the hemorrhagic brain, as was documented in our study, suggests its pathogenetic implication in ICH, and provides the feasibility of the AT1R blockers. On the other hand, when AT1 receptors are inhibited, angiotensin II can increasingly interact with AT2 receptors, because telmisartan selectively blocks the AT1 receptors and allows the angiotensin II to stimulate the unoccupied AT2 receptors (Iwai et al., 2004). This dual effect of telmisartan may be the cause of their superiority over the ACE inhibitors in ICH treatment. Evidences have been more recently gathered suggesting that the stimulation of AT2R can offset or oppose, by cross-talk mechanisms, the AT1 mediated actions of angiotensin II on blood pressure regulation, vascular reactivity, cell growth, and apoptosis (Wright et al., 2002;
Wu et al., 2002). The relative stimulation of the AT2R, as an indirect result of AT1R antagonism, may contribute to the overall effects of the AT1R antagonists during pathophysiological process of ICH. However, the relationship between telmisartan and AT receptor subtype is not necessarily straightforward and warrants further study.

The inhibition of AT1R induces eNOS expression in injured tissue via the activation of AT2R (Thai et al., 2003). The telmisartan-induced activation of eNOS may perform a function relevant to the preservation of cerebral blood flow and the attenuation of neurological loss in the perihematomal regions (Jung et al., 2004; Endres et al., 2004). In addition, nitric oxide from eNOS can be protective against oxidative stress and excitotoxic damage (Iadecola 1997; Agnoletti et al. 1999), and reduce the brain edema (Lee et al., 2006). However, nitric oxide might aggravate the ICH conditions via inhibiting platelet activation and preventing thrombosis (Stagliano et al., 1997). Additional genetic controls, including pharmacologic blocking, or genetic knockdown of eNOS would be helpful to verify a role of telmisartan-induced eNOS.

Apoptosis represents a prominent feature of ICH-associated cell death in the perihematomal region (Qureshi et al., 2003). In cells responsive to apoptotic stimuli, two major apoptosis pathways have been identified; the intrinsic apoptotic pathway, which includes mitochondria-involved signaling and caspase-9, and the extrinsic
apoptotic pathway, which is mediated principally by death receptors and caspase-8 (Qureshi et al., 2003; Huang et al., 2004). Since telmisartan attenuated the activities of caspase-9, caspase-3, and caspase-8, and the mRNA levels of Fas-L and TNF-α, we speculate telmisartan can alleviate both the intrinsic and extrinsic apoptotic pathway activation associated with ICH. On the other hand, a variety of experimental and human studies regarding ICH has revealed that inflammation can be a major target of novel therapies for ICH (Chu et al., 2004; Jung et al., 2004; Lee et al., 2006). In line with reports that some ARBs exerted anti-inflammatory effects (Kramer et al., 2002; Nagai et al., 2006), telmisartan in our study could inhibit the number of infiltrating leukocytes and activated microglia, and the expression of COX2 in the hemorrhagic brain.

Oxidative stress during ICH is another critical event, which leads to the disruption of the BBB, combined with hematoma expansion and secondary vasogenic edema (Tang et al., 2005). Angiotensin II is one of the most important known oxidative stress inducers, and produce reactive oxygen species by the enzyme NADPH oxidase (Berry et al., 2001; Cai et al., 2003). The reduced levels of the superoxide and lipid peroxidation product by telmisartan might contribute to a remarkable reduction in the hematoma growth and edema.

Recent evidences suggest that PPARγ activation represents a novel mechanism
for the beneficial effects of ARBs (Benson et al., 2004; Schupp et al., 2004). Telmisartan can function as a partial agonist of PPARγ (Benson et al., 2004). The ability of telmisartan to activate PPARγ appears to be independent of AT1R blockade, as it can activate PPARγ in cells that lack AT1R (Schupp et al., 2004). PPARγ activators can ameliorate multiple pathogenetic determinants of atherosclerosis, ischemia, or inflammation (Schiffrin et al., 2003). Thus, some interest exists in the potential use of PPARγ activators for treatment of ICH. In our study, the administration of telmisartan at the onset of ICH coincided with the activation of PPARγ, and suppression of inflammation and oxidative stress. The PPARγ activation induces the catalase gene expression and protein. The inducibility of the catalase gene could play an important role in combating the oxidative stress induced by ICH (Nakamura et al., 2005). It has also been postulated that the beneficial effect of PPARγ agonists in stroke is because of their anti-inflammatory effect. Most of the pro-inflammatory responses are amplified and regulated by the transcription factor, NF-kB. PPARγ agonists have been shown to inhibit NF-kB, either directly by interacting with its subunits, competing for common transcription coactivators or through upregulation of its inhibitory protein, inhibitor kBa (Delerive et al., 2000). In a recent study, 15d-PGJ2, a PPARγ agonist, could elevate the catalase expression, suppress the NF-kB activity, and restrict neutrophil infiltration.
(Zhao et al., 2006). It is therefore likely that the upregulation of PPARγ by telmisartan, as shown in the present study, may provide an explanation for the anti-oxidative and anti-inflammatory effects of telmisartan. By virtue of its unique ability to activate PPARγ at reasonable concentrations, telmisartan may have a greater potential than other ARBs to improve the hostile environments of the hemorrhagic brain.

In conclusion, we provide convincing evidences to suggest that telmisartan does, indeed, exert therapeutic effects in experimental ICH. Telmisartan is widely used in the current clinical field, as an antihypertensive agent. Considering that the use of antihypertensive agents in ICH patients is seldom contraindicated, the clinical use of telmisartan in cases of ICH may be an option with a fair degree of feasibility.
REFERENCES


Footnotes

a) Financial support

This study was supported by the Ministry of Health and Welfare (A050230), Republic of Korea.

b) The name and full address and e-mail address of person to receive reprint requests.

Jae-Kyu Roh, MD, PhD.
Department of Neurology, Seoul National University Hospital
28, Yongon-Dong, Chongro-Gu, Seoul, 110-744, Republic of Korea.
Phone: +82-2-2072-3265 / Fax: +82-2-3672-4949 / e-mail: rohjk@snu.ac.kr

c) Contribution

The first two authors contributed equally to this work (K-H Jung and K Chu).
Legends for figures

Figure 1. Behavioral test, Hemorrhage volume, and brain water content.

In the MLPT (a), the ICH-TMS group exhibited less pronounced initial deficits, and recovered better than did the ICH-only group. Telmisartan reduced the hemorrhage volume by 55% at 24 hours, and 83% at 72 hours, compared to the ICH-only group (b). Telmisartan significantly reduced brain water contents on the ipsilateral side following collagenase-induced ICH (c) and autologous blood-induced ICH (d), as compared to what was observed in the ICH-only group at 72 hours (c). *p<0.05 vs ICH-only (n=6, t-test).

Figure 2. Histological analysis of apoptosis and inflammation.

Telmisartan reduced the number of TUNEL+, OX42+ and MPO+ cells in the perihematomal regions (a). Quantification analysis revealed significant reductions in the quantities of TUNEL+, OX42+ and MPO+ cells in the ICH-TMS group, compared to the ICH-only group (b). Bar=50µm. *p<0.05 vs ICH-only (n=6, t-test).

Figure 3. Western blotting and Caspase activity assay.

Western blotting (a) revealed the nuclear and cytosolic fractions of PPARγ, the eNOS
and the COX-2 expression. Densitometric analysis of the band indicated an increase in
the nuclear fraction of PPARγ and the eNOS expression, and a decrease in the COX-2
expression in the ICH-TMS group. Telmisartan significantly reduced the activity of all
of the tested caspases, caspase-8, caspase-9, and caspase-3 (f). The Densitometric data
are representative of 3 experiments. *p<0.0 vs ICH-only (n=3, Mann-Whitney U test).

Figure 4. RT-PCR for AT1, AT2, TNF-alpha, IL-6, Fas, and Fas-L expression.

RT-PCR results were analyzed in terms of the optical density ratio to the GAPDH (a).
AT1 was upregulated in the hemorrhagic compared with the normal samples, and this
was also apparent in the ICH-TMS group (b). AT2, however, exhibited no changes.
Whereas the ICH-only group exhibited upregulations in TNF-alpha, Fas, and Fas-L, the
ICH-TMS rats exhibited reduced expressions of all of these molecules (c). *p<0.05 vs
normal in (b) and vs ICH-only in (c) (n=3, Mann-Whitney U test).

Figure 5. Anti-oxidant effects of telmisartan.

Fluorescent images after incubation with DHE demonstrated that basal superoxide
levels were increased in the hemorrhagic brains, and that telmisartan treatment effected
a reduction in the DHE fluorescence, which indicated reduced superoxide generation (a-
c). Quantitative measurements of DHE fluorescence (b) indicated a 74% decrease in the ICH-TMS group, as compared with the ICH-only group. Bar=50 µm. *p<0.01 vs ICH-only (n=6, ANOVA and Tukey's test). Telmisartan significantly decreased the elevated MDA content in rat brain after ICH. *p<0.05 vs ICH-only (n=3, Mann-Whitney U test).
<table>
<thead>
<tr>
<th></th>
<th>ICH-only</th>
<th>ICH-TMS</th>
</tr>
</thead>
<tbody>
<tr>
<td>PPAR-r (Nu)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PPAR-r (Cy)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>eNOS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COX2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Actin</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Bar Graphs:**

- **b**: Relative OD for cytosolic PPAR-r
- **c**: Relative OD for nuclear PPAR-r
- **d**: Relative OD for eNOS
- **e**: Relative OD for COX-2
- **f**: Caspase activity

*Note: The asterisk (*) indicates statistical significance.*
a

AT-1
AT-2
TNF-α
Fas
Fas-L
GAPDH

Normal  ICH-only  ICH-TMS

b

AT1R
AT2R

Relative optical density

Normal  ICH-only  TMS

Relative optical density

TNF-α  Fas  Fas-L

Relative optical density

*